Hope is always welcome and on the right time.While it may not be whole remedy eliminating the problem this new health solution will atleast shoulder of financial burden.
The National Hospital Insurance Fund (NHIF) has unveiled a joint partnership to enhance access to a crucial drug for local prostate cancer patients.
The partnership will see Janssen one of the pharmaceutical companies of Johnson &Johnson, make one of its innovative medicines used for the treatment of advanced prostate cancer available at a subsidized rate for NHIF members.
The Janssen Kenya Prostate cancer program in conjunction with Axios International, a specialized healthcare access company, will provide significant cost savings to NHIF members, and seeks to support efforts by NHIF to adopt new low-cost service delivery models by embracing public-private partnerships (PPPs).
According to Janssen Kenya Country Manager Mr. Marseille Onyango, the prescription drug, Zytiga (Abiraterone will be available to NHIF members from selected public and private medical facilities.
As part of the commitment, Onyango, said the firm will make the treatment available at a discounted price for NHIF members as part of a corporate commitment to strengthen cancer care in sub-Sahara Africa.
“At Janssen Kenya, we are working hard to enhance access to our innovative medicines while leveraging partnerships and collaborations with key stakeholders such as NHIFto make a significant impact in the lives of cancer patients,” Onyango said.